{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:47:29Z","timestamp":1792784849694,"version":"4.5.0"},"reference-count":246,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIHR Oxford Health Biomedical Research Centre"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Impaired cognition is often overlooked in the clinical management of depression, despite its association with poor psychosocial functioning and reduced clinical engagement. There is an outstanding need for new treatments to address this unmet clinical need, highlighted by our consultations with individuals with lived experience of depression. Here we consider the evidence to support different pharmacological approaches for the treatment of impaired cognition in individuals with depression, including treatments that influence primary neurotransmission directly as well as novel targets such as neurosteroid modulation. We also consider potential methodological challenges in establishing a strong evidence base in this area, including the need to disentangle direct effects of treatment on cognition from more generalised symptomatic improvement and the identification of sensitive, reliable and objective measures of cognition.<\/jats:p>","DOI":"10.1038\/s41398-022-02249-6","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T08:04:14Z","timestamp":1668672254000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7846-2879","authenticated-orcid":false,"given":"Michael J.","family":"Colwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosana","family":"Tagomori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-6138","authenticated-orcid":false,"given":"Philip J.","family":"Cowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1609-8335","authenticated-orcid":false,"given":"Catherine J.","family":"Harmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8995-2099","authenticated-orcid":false,"given":"Susannah E.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"2249_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/npp.2011.183","volume":"37","author":"JP Roiser","year":"2012","unstructured":"Roiser JP, Elliott R, Sahakian BJ. Cognitive Mechanisms of Treatment in Depression. Neuropsychopharmacology 2012;37:117\u201336.","journal-title":"Neuropsychopharmacology"},{"key":"2249_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejphar.2009.08.046","volume":"626","author":"D Marazziti","year":"2010","unstructured":"Marazziti D, Consoli G, Picchetti M, Carlini M, Faravelli L. Cognitive impairment in major depression. Eur J Pharm. 2010;626:83\u201386.","journal-title":"Eur J Pharm"},{"key":"2249_CR3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.pnpbp.2019.02.015","volume":"92","author":"D Zaremba","year":"2019","unstructured":"Zaremba D, Schulze Kalthoff I, F\u00f6rster K, Redlich R, Grotegerd D, Leehr EJ, et al. The effects of processing speed on memory impairment in patients with major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2019;92:494\u2013500.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2249_CR4","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1017\/S0033291710001911","volume":"41","author":"HJ Conradi","year":"2011","unstructured":"Conradi HJ, Ormel J, De Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011;41:1165.","journal-title":"Psychol Med"},{"key":"2249_CR5","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2147\/NDT.S199746","volume":"15","author":"G Perini","year":"2019","unstructured":"Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat. 2019;15:1249\u201358.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2249_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1017\/S1092852918001062","volume":"24","author":"KW Miskowiak","year":"2019","unstructured":"Miskowiak KW, Petersen CS. Neuronal underpinnings of cognitive impairment and - improvement in mood disorders. CNS Spectr. 2019;24:30\u201353.","journal-title":"CNS Spectr"},{"key":"2249_CR7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.12740\/PP\/OnlineFirst\/105415","volume":"54","author":"A Czerwi\u0144ska","year":"2020","unstructured":"Czerwi\u0144ska A, Paw\u0142owski T. Cognitive dysfunctions in depression\u2013significance, description and treatment prospects. Psychiatr Pol. 2020;54:453\u201366.","journal-title":"Psychiatr Pol"},{"key":"2249_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jad.2018.04.051","volume":"235","author":"MJ Knight","year":"2018","unstructured":"Knight MJ, Air T, Baune BT. The role of cognitive impairment in psychosocial functioning in remitted depression. J Affect Disord. 2018;235:129\u201334.","journal-title":"J Affect Disord"},{"key":"2249_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1017\/S1355617714000198","volume":"20","author":"AM Koenig","year":"2014","unstructured":"Koenig AM, Bhalla RK, Butters MA. Cognitive functioning and late-life depression. J Int Neuropsychol Soc Jins 2014;20:461.","journal-title":"J Int Neuropsychol Soc Jins"},{"key":"2249_CR10","doi-asserted-by":"publisher","first-page":"152147","DOI":"10.1016\/j.comppsych.2019.152147","volume":"97","author":"MJ Knight","year":"2020","unstructured":"Knight MJ, Lyrtzis E, Baune BT. The association of cognitive deficits with mental and physical Quality of Life in Major Depressive Disorder. Compr Psychiatry. 2020;97:152147.","journal-title":"Compr Psychiatry"},{"key":"2249_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-7-32","volume":"7","author":"SL Naismith","year":"2007","unstructured":"Naismith SL, Longley WA, Scott EM, Hickie IB. Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study. BMC Psychiatry. 2007;7:32.","journal-title":"BMC Psychiatry"},{"key":"2249_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/070674371405901206","volume":"59","author":"RW Lam","year":"2014","unstructured":"Lam RW, Kennedy SH, Mclntyre RS, Khullar A. Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. Can J Psychiatry. 2014;59:649\u201354.","journal-title":"Can J Psychiatry"},{"key":"2249_CR13","unstructured":"The National Institute for Health and Care Excellence. Depression in adults: recognition and management. Clinical guideline [CG90]. 2009. https:\/\/www.nice.org.uk\/guidance\/cg90. Accessed 4 February 2021."},{"key":"2249_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.7326\/M15-2570","volume":"164","author":"A Qaseem","year":"2016","unstructured":"Qaseem A, Barry MJ, Kansagara D. Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients With Major Depressive Disorder: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;164:350\u20139.","journal-title":"Ann Intern Med"},{"key":"2249_CR15","doi-asserted-by":"crossref","unstructured":"Schneider F, H\u00e4rter M, Schorr S S3-Leitlinie\/Nationale VersorgungsLeitlinie Unipolare Depression. Springer-Verlag; 2017.","DOI":"10.1007\/978-3-662-52906-5"},{"key":"2249_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0005-7894(01)80004-6","volume":"32","author":"SD Hollon","year":"2001","unstructured":"Hollon SD, Shelton RC. Treatment guidelines for major depressive disorder. Behav Ther. 2001;32:235\u201358.","journal-title":"Behav Ther"},{"key":"2249_CR17","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.neuroimage.2015.10.069","volume":"125","author":"N Cohen","year":"2016","unstructured":"Cohen N, Margulies DS, Ashkenazi S, Schaefer A, Taubert M, Henik A, et al. Using executive control training to suppress amygdala reactivity to aversive information. Neuroimage 2016;125:1022\u201331.","journal-title":"Neuroimage"},{"key":"2249_CR18","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1017\/S1352465814000046","volume":"43","author":"AW Calkins","year":"2015","unstructured":"Calkins AW, McMorran KE, Siegle GJ, Otto MW. The effects of computerized cognitive control training on community adults with depressed mood. Behav Cogn Psychother. 2015;43:578\u201389.","journal-title":"Behav Cogn Psychother"},{"key":"2249_CR19","doi-asserted-by":"publisher","first-page":"103783","DOI":"10.1016\/j.brat.2020.103783","volume":"136","author":"DJ Hallford","year":"2021","unstructured":"Hallford DJ, Austin DW, Takano K, Fuller-Tyszkiewicz M, Raes F. Computerized Memory Specificity Training (c-MeST) for major depression: A randomised controlled trial. Behav Res Ther. 2021;136:103783.","journal-title":"Behav Res Ther"},{"key":"2249_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jad.2016.03.066","volume":"202","author":"AR Brunoni","year":"2016","unstructured":"Brunoni AR, Tortella G, Bense\u00f1or IM, Lotufo PA, Carvalho AF, Fregni F. Cognitive effects of transcranial direct current stimulation in depression: results from the SELECT-TDCS trial and insights for further clinical trials. J Affect Disord. 2016;202:46\u201352.","journal-title":"J Affect Disord"},{"key":"2249_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.psychres.2014.05.013","volume":"219","author":"BT Baune","year":"2014","unstructured":"Baune BT, Renger L. Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression \u2013 A systematic review. Psychiatry Res. 2014;219:25\u201350.","journal-title":"Psychiatry Res"},{"key":"2249_CR22","doi-asserted-by":"publisher","first-page":"0","DOI":"10.4088\/JCP.13r08609","volume":"75","author":"RSE Keefe","year":"2014","unstructured":"Keefe RSE, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M. Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. J Clin Psychiatry. 2014;75:0.","journal-title":"J Clin Psychiatry"},{"key":"2249_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11065-018-9369-5","volume":"28","author":"CE Prado","year":"2018","unstructured":"Prado CE, Watt S, Crowe SF. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychol Rev. 2018;28:32\u201372.","journal-title":"Neuropsychol Rev"},{"key":"2249_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1017\/S1092852915000334","volume":"20","author":"SM Stahl","year":"2015","unstructured":"Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin\u2019s downstream effects on glutamate and GABA (gamma amino butyric acid) release. CNS Spectr. 2015;20:331\u20136.","journal-title":"CNS Spectr"},{"key":"2249_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt215","volume":"5","author":"D Cutuli","year":"2013","unstructured":"Cutuli D, De Bartolo P, Caporali P, Tartaglione AM, Oddi D, D\u2019Amato FR, et al. Neuroprotective effects of donepezil against cholinergic depletion. Alzheimers Res Ther. 2013;5:1\u201318.","journal-title":"Alzheimers Res Ther"},{"key":"2249_CR26","doi-asserted-by":"crossref","unstructured":"Rosenblat JD, Kakar R, McIntyre RS. The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Int J Neuropsychopharmacol. 2016;19:pyv082.","DOI":"10.1093\/ijnp\/pyv082"},{"key":"2249_CR27","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S2215-0366(16)00012-2","volume":"3","author":"C Shilyansky","year":"2016","unstructured":"Shilyansky C, Williams LM, Gyurak A, Harris A, Usherwood T, Etkin A. Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study. Lancet Psychiatry. 2016;3:425\u201335.","journal-title":"Lancet Psychiatry"},{"key":"2249_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/13546800600714791","volume":"12","author":"D Lahr","year":"2007","unstructured":"Lahr D, Beblo T, Hartje W. Cognitive performance and subjective complaints before and after remission of major depression. Cogn Neuropsychiatry. 2007;12:25\u201345.","journal-title":"Cogn Neuropsychiatry"},{"key":"2249_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jad.2010.11.011","volume":"134","author":"BJ Hasselbalch","year":"2011","unstructured":"Hasselbalch BJ, Knorr U, Kessing LV. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J Affect Disord. 2011;134:20\u201331.","journal-title":"J Affect Disord"},{"key":"2249_CR30","unstructured":"Organization WH ICD-10: international statistical classification of diseases and related health problems: tenth revision. 1994."},{"key":"2249_CR31","unstructured":"Association AP Diagnostic and statistical manual of mental disorders: DSM-5TM, 5th ed. Arlington, VA, US: American Psychiatric Publishing, Inc.; 2013."},{"key":"2249_CR32","doi-asserted-by":"crossref","unstructured":"Beck AT, Steer RA, Brown GK Beck depression inventory (BDI-II). vol. 10. Pearson; 1996.","DOI":"10.1037\/t00742-000"},{"key":"2249_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0165-0327(00)00309-8","volume":"66","author":"P Bech","year":"2001","unstructured":"Bech P, Rasmussen N-A, Olsen LR, Noerholm V, Abildgaard W. The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. J Affect Disord. 2001;66:159\u201364.","journal-title":"J Affect Disord"},{"key":"2249_CR34","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JBW. The PHQ\u20109: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606\u201313.","journal-title":"J Gen Intern Med"},{"key":"2249_CR35","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3389\/fnins.2013.00198","volume":"7","author":"IP Ilieva","year":"2013","unstructured":"Ilieva IP, Farah MJ. Enhancement stimulants: perceived motivational and cognitive advantages. Front Neurosci. 2013;7:198.","journal-title":"Front Neurosci"},{"key":"2249_CR36","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bdi.12534","volume":"19","author":"KW Miskowiak","year":"2017","unstructured":"Miskowiak KW, Burdick KE, Martinez\u2010Aran A, Bonnin CM, Bowie CR, Carvalho AF, et al. Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disord. 2017;19:614\u201326.","journal-title":"Bipolar Disord"},{"key":"2249_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-021-01568-4","volume":"11","author":"AN de Cates","year":"2021","unstructured":"de Cates AN, Wright LC, Martens MAG, Gibson D, T\u00fcrkmen C, Filippini N, et al. D\u00e9j\u00e0-vu? Neural and behavioural effects of the 5-HT4 receptor agonist, prucalopride, in a hippocampal-dependent memory task. Transl Psychiatry. 2021;11:1\u20139.","journal-title":"Transl Psychiatry"},{"key":"2249_CR38","unstructured":"Parker J Brintellix\u00ae (Vortioxetine) - Psychopharmacologic Drugs Advisory Committee. Maryland; 2016."},{"key":"2249_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","volume":"145","author":"C Sanchez","year":"2015","unstructured":"Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharm Ther. 2015;145:43\u201357.","journal-title":"Pharm Ther"},{"key":"2249_CR40","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.biopsych.2021.02.084","volume":"89","author":"A Pehrson","year":"2021","unstructured":"Pehrson A, Li Y, Sanchez C, Gulinello M. Vortioxetine Improves Mood and Cognitive Function in Animal Models of Psychiatric Disease: Relevance of 5-HT3 Receptor-Mediated Regulation of GABA and Glutamate Neurotransmission. Biol Psychiatry. 2021;89:S26.","journal-title":"Biol Psychiatry"},{"key":"2249_CR41","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1007\/s40265-016-0655-3","volume":"76","author":"JE Frampton","year":"2016","unstructured":"Frampton JE. Vortioxetine: A Review in Cognitive Dysfunction in Depression. Drugs 2016;76:1675\u201382.","journal-title":"Drugs"},{"key":"2249_CR42","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1017\/S1461145714000546","volume":"17","author":"RS McIntyre","year":"2014","unstructured":"McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17:1557\u201367.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2249_CR43","doi-asserted-by":"publisher","first-page":"0","DOI":"10.4088\/JCP.16m10744","volume":"78","author":"RS McIntyre","year":"2017","unstructured":"McIntyre RS, Florea I, Tonnoir B, Loft H, Lam RW, Christensen MC. Efficacy of vortioxetine on cognitive functioning in working patients with major depressive disorder. J Clin Psychiatry. 2017;78:0.","journal-title":"J Clin Psychiatry"},{"key":"2249_CR44","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/JCP.0000000000000941","volume":"38","author":"J Jaeger","year":"2018","unstructured":"Jaeger J. Digit Symbol Substitution Test: The Case for Sensitivity Over Specificity in Neuropsychological Testing. J Clin Psychopharmacol. 2018;38:513\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"2249_CR45","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1192\/bjp.180.5.396","volume":"180","author":"D Smith","year":"2002","unstructured":"Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. Br J Psychiatry. 2002;180:396\u2013404.","journal-title":"Br J Psychiatry"},{"key":"2249_CR46","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/clpt.2013.39","volume":"93","author":"EL Theunissen","year":"2013","unstructured":"Theunissen EL, Street D, H\u00f8jer A-M, Vermeeren A, van Oers A, Ramaekers JG. A Randomized Trial on the Acute and Steady-State Effects of a New Antidepressant, Vortioxetine (Lu AA21004), on Actual Driving and Cognition. Clin Pharm Ther. 2013;93:493\u2013501.","journal-title":"Clin Pharm Ther"},{"key":"2249_CR47","doi-asserted-by":"crossref","unstructured":"McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. Int J Neuropsychopharmacol. 2016;19:pyw055.","DOI":"10.1093\/ijnp\/pyw055"},{"key":"2249_CR48","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0165-0327(00)00242-1","volume":"64","author":"P Svanborg","year":"2001","unstructured":"Svanborg P, \u00c5sberg M. A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery \u00c5sberg Depression Rating Scale (MADRS). J Affect Disord. 2001;64:203\u201316.","journal-title":"J Affect Disord"},{"key":"2249_CR49","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1002\/sim.1296","volume":"21","author":"SJ Pocock","year":"2002","unstructured":"Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems. Stat Med. 2002;21:2917\u201330.","journal-title":"Stat Med"},{"key":"2249_CR50","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1037\/a0028813","volume":"121","author":"MT Treadway","year":"2012","unstructured":"Treadway MT, Bossaller NA, Shelton RC, Zald DH. Effort-based decision-making in major depressive disorder: a translational model of motivational anhedonia. J Abnorm Psychol. 2012;121:553.","journal-title":"J Abnorm Psychol"},{"key":"2249_CR51","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1037\/a0036754","volume":"14","author":"SM Ravizza","year":"2014","unstructured":"Ravizza SM, Delgado MR. Motivational enhancement of cognitive control depends on depressive symptoms. Emotion 2014;14:646\u201350.","journal-title":"Emotion"},{"key":"2249_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fpsyt.2019.00017","volume":"10","author":"B Cao","year":"2019","unstructured":"Cao B, Park C, Subramaniapillai M, Lee Y, Iacobucci M, Mansur RB, et al. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder. Front Psychiatry. 2019;10:17.","journal-title":"Front Psychiatry"},{"key":"2249_CR53","doi-asserted-by":"publisher","first-page":"796","DOI":"10.30773\/pi.2020.0017","volume":"17","author":"C Shin","year":"2020","unstructured":"Shin C, Ko Y-H, Shim S-H, Kim JS, Na K-S, Hahn S-W, et al. Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial. Psychiatry Investig. 2020;17:796\u2013803.","journal-title":"Psychiatry Investig"},{"key":"2249_CR54","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/0269881107068066","volume":"21","author":"SR Chamberlain","year":"2007","unstructured":"Chamberlain SR, M\u00fcller U, Deakin JB, Corlett PR, Dowson J, Cardinal RN, et al. Lack of deleterious effects of buspirone on cognition in healthy male volunteers. J Psychopharmacol. 2007;21:210\u20135.","journal-title":"J Psychopharmacol"},{"key":"2249_CR55","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/sj.npp.1300390","volume":"29","author":"RA Bantick","year":"2004","unstructured":"Bantick RA, Rabiner EA, Hirani E, de Vries MH, Hume SP, Grasby PM. Occupancy of agonist drugs at the 5-HT 1A receptor. Neuropsychopharmacology 2004;29:847\u201359.","journal-title":"Neuropsychopharmacology"},{"key":"2249_CR56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jpsychires.2019.04.024","volume":"114","author":"H Chen","year":"2019","unstructured":"Chen H, Lin Q, Lin T, Lin Y, Lin X, Chen R, et al. A controlled study of the efficacy and safety of tandospirone citrate combined with escitalopram in the treatment of vascular depression: A pilot randomized controlled trial at a single-center in China. J Psychiatr Res. 2019;114:133\u201340.","journal-title":"J Psychiatr Res"},{"key":"2249_CR57","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1176\/appi.ajp.160.2.334","volume":"160","author":"F Yasuno","year":"2003","unstructured":"Yasuno F, Suhara T, Nakayama T, Ichimiya T, Okubo Y, Takano A, et al. Inhibitory Effect of Hippocampal 5-HT1A Receptors on Human Explicit Memory. Am J Psychiatry. 2003;160:334\u201340.","journal-title":"Am J Psychiatry"},{"key":"2249_CR58","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.brainres.2012.04.032","volume":"1461","author":"C Loane","year":"2012","unstructured":"Loane C, Politis M. Buspirone: What is it all about? Brain Res. 2012;1461:111\u20138.","journal-title":"Brain Res"},{"key":"2249_CR59","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1017\/S0033291720000604","volume":"51","author":"SE Murphy","year":"2021","unstructured":"Murphy SE, De Cates AN, Gillespie AL, Godlewska BR, Scaife JC, Wright LC, et al. Translating the promise of 5HT4 receptor agonists for the treatment of depression. Psychol Med. 2021;51:1111\u201320.","journal-title":"Psychol Med"},{"key":"2249_CR60","doi-asserted-by":"publisher","first-page":"7160","DOI":"10.1021\/jm5003952","volume":"57","author":"B Benhamu\u0301","year":"2014","unstructured":"Benhamu\u0301 B, Mart\u00edn-Fontecha M, Va\u0301zquez-Villa H, Pardo L, L\u00f3pez-Rodr\u00edguez ML. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer\u2019s disease. J Med Chem. 2014;57:7160\u201381.","journal-title":"J Med Chem"},{"key":"2249_CR61","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3389\/fpsyt.2021.623684","volume":"12","author":"R Okubo","year":"2021","unstructured":"Okubo R, Hasegawa T, Fukuyama K, Shiroyama T, Okada M. Current limitations and candidate potential of 5-ht7 receptor antagonism in psychiatric pharmacotherapy. Front Psychiatry. 2021;12:161.","journal-title":"Front Psychiatry"},{"key":"2249_CR62","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.tips.2008.07.001","volume":"29","author":"MV King","year":"2008","unstructured":"King MV, Marsden CA, Fone KCF. A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharm Sci. 2008;29:482\u201392.","journal-title":"Trends Pharm Sci"},{"key":"2249_CR63","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.nurt.2008.05.008","volume":"5","author":"N Upton","year":"2008","unstructured":"Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 Receptor Antagonists as Novel Cognitive Enhancing Agents for Alzheimer\u2019s Disease. Neurotherapeutics 2008;5:458\u201369.","journal-title":"Neurotherapeutics"},{"key":"2249_CR64","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fphar.2015.00162","volume":"6","author":"O Stiedl","year":"2015","unstructured":"Stiedl O, Pappa E, Konradsson-Geuken \u00c5, \u00d6gren SO. The role of the serotonin receptor subtypes 5-HT1A and 5-HT7 and its interaction in emotional learning and memory. Front Pharm. 2015;6:162.","journal-title":"Front Pharm"},{"key":"2249_CR65","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.bbr.2013.04.008","volume":"248","author":"A Nikiforuk","year":"2013","unstructured":"Nikiforuk A, Popik P. Amisulpride promotes cognitive flexibility in rats: The role of 5-HT7 receptors. Behav Brain Res. 2013;248:136\u201340.","journal-title":"Behav Brain Res"},{"key":"2249_CR66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.bbr.2007.12.012","volume":"195","author":"A Cifariello","year":"2008","unstructured":"Cifariello A, Pompili A, Gasbarri A. 5-HT7 receptors in the modulation of cognitive processes. Behav Brain Res. 2008;195:171\u20139.","journal-title":"Behav Brain Res"},{"key":"2249_CR67","doi-asserted-by":"publisher","first-page":"105185","DOI":"10.1016\/j.neuint.2021.105185","volume":"150","author":"M Solas","year":"2021","unstructured":"Solas M, Van Dam D, Janssens J, Ocariz U, Vermeiren Y, De Deyn PP, et al. 5-HT7 receptors in Alzheimer\u2019s disease. Neurochem Int. 2021;150:105185.","journal-title":"Neurochem Int"},{"key":"2249_CR68","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.coph.2011.01.004","volume":"11","author":"X Codony","year":"2011","unstructured":"Codony X, Vela JM, Ram\u00edrez MJ. 5-HT6 receptor and cognition. Curr Opin Pharm. 2011;11:94\u2013100.","journal-title":"Curr Opin Pharm"},{"key":"2249_CR69","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/emmm.201201410","volume":"4","author":"J Meffre","year":"2012","unstructured":"Meffre J, Chaumont\u2010Dubel S, Mannoury la Cour C, Loiseau F, Watson DJG, Dekeyne A, et al. 5\u2010HT6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia. EMBO Mol Med. 2012;4:1043\u201356.","journal-title":"EMBO Mol Med"},{"key":"2249_CR70","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.drudis.2006.02.004","volume":"11","author":"J Holenz","year":"2006","unstructured":"Holenz J, Pauwels PJ, D\u00edaz JL, Merc\u00e8 R, Codony X, Buschmann H. Medicinal chemistry strategies to 5-HT6 receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Disco Today. 2006;11:283\u201399.","journal-title":"Drug Disco Today"},{"key":"2249_CR71","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/13543784.2018.1483334","volume":"27","author":"R Khoury","year":"2018","unstructured":"Khoury R, Grysman N, Gold J, Patel K, Grossberg GT. The role of 5 HT6-receptor antagonists in Alzheimer\u2019s disease: an update. Expert Opin Investig Drugs. 2018;27:523\u201333.","journal-title":"Expert Opin Investig Drugs"},{"key":"2249_CR72","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/cercor\/bhy264","volume":"29","author":"G Shafiei","year":"2019","unstructured":"Shafiei G, Zeighami Y, Clark CA, Coull JT, Nagano-Saito A, Leyton M, et al. Dopamine Signaling Modulates the Stability and Integration of Intrinsic Brain Networks. Cereb Cortex. 2019;29:397\u2013409.","journal-title":"Cereb Cortex"},{"key":"2249_CR73","doi-asserted-by":"publisher","first-page":"623.e15","DOI":"10.1016\/j.neurobiolaging.2011.03.002","volume":"33","author":"EC Klostermann","year":"2012","unstructured":"Klostermann EC, Braskie MN, Landau SM, O\u2019Neil JP, Jagust WJ. Dopamine and frontostriatal networks in cognitive aging. Neurobiol Aging. 2012;33:623.e15\u2013623.e24.","journal-title":"Neurobiol Aging"},{"key":"2249_CR74","doi-asserted-by":"publisher","first-page":"113514","DOI":"10.1016\/j.expneurol.2020.113514","volume":"335","author":"JS Schneider","year":"2021","unstructured":"Schneider JS, Marshall CA, Keibel L, Snyder NW, Hill MP, Brotchie JM, et al. A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson\u2019s disease. Exp Neurol. 2021;335:113514.","journal-title":"Exp Neurol"},{"key":"2249_CR75","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/wcs.1401","volume":"7","author":"R Cools","year":"2016","unstructured":"Cools R. The costs and benefits of brain dopamine for cognitive control. Wiley Interdiscip Rev Cogn Sci. 2016;7:317\u201329.","journal-title":"Wiley Interdiscip Rev Cogn Sci"},{"key":"2249_CR76","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1093\/cercor\/bhx253","volume":"28","author":"M L\u00f6vd\u00e9n","year":"2018","unstructured":"L\u00f6vd\u00e9n M, Karalija N, Andersson M, W\u00e5hlin A, Axelsson J, K\u00f6hncke Y, et al. Latent-Profile Analysis Reveals Behavioral and Brain Correlates of Dopamine-Cognition Associations. Cereb Cortex. 2018;28:3894\u2013907.","journal-title":"Cereb Cortex"},{"key":"2249_CR77","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0269881117731472","volume":"32","author":"C Klinge","year":"2018","unstructured":"Klinge C, Shuttleworth C, Muglia P, Nobre AC, Harmer CJ, Murphy SE. Methylphenidate enhances implicit learning in healthy adults. J Psychopharmacol. 2018;32:70\u201380.","journal-title":"J Psychopharmacol"},{"key":"2249_CR78","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.psychres.2007.04.012","volume":"160","author":"I Herrera-Guzm\u00e1n","year":"2008","unstructured":"Herrera-Guzm\u00e1n I, Gudayol-Ferr\u00e9 E, Lira-Mandujano J, Herrera-Abarca J, Herrera-Guzm\u00e1n D, Montoya-P\u00e9rez K, et al. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. Psychiatry Res. 2008;160:72\u201382.","journal-title":"Psychiatry Res"},{"key":"2249_CR79","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.psychres.2014.06.053","volume":"220","author":"JK Soczynska","year":"2014","unstructured":"Soczynska JK, Ravindran LN, Styra R, McIntyre RS, Cyriac A, Manierka MS, et al. The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: Results from a randomized controlled trial. Psychiatry Res. 2014;220:245\u201350.","journal-title":"Psychiatry Res"},{"key":"2249_CR80","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00213-005-0128-y","volume":"182","author":"M Siepmann","year":"2005","unstructured":"Siepmann M, Werner K, Schindler C, Oertel R, Kirch W. The effects of bupropion on cognitive functions in healthy subjects. Psychopharmacol (Berl). 2005;182:597\u20138.","journal-title":"Psychopharmacol (Berl)"},{"key":"2249_CR81","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/01.jcp.0000104910.75206.b9","volume":"24","author":"C DeBattista","year":"2004","unstructured":"DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol. 2004;24:87\u201390.","journal-title":"J Clin Psychopharmacol"},{"key":"2249_CR82","first-page":"115","volume":"2","author":"M Kaser","year":"2017","unstructured":"Kaser M, Deakin JB, Michael A, Zapata C, Bansal R, Ryan D, et al. Modafinil Improves Episodic Memory and Working Memory Cognition in Patients With Remitted Depression: A Double-Blind, Randomized, Placebo-Controlled Study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017;2:115\u201322.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"2249_CR83","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.euroneuro.2015.07.028","volume":"25","author":"RM Battleday","year":"2015","unstructured":"Battleday RM, Brem A-K. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. Eur Neuropsychopharmacol. 2015;25:1865\u201381.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2249_CR84","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s00213-002-1250-8","volume":"165","author":"DC Turner","year":"2003","unstructured":"Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacol (Berl). 2003;165:260\u20139.","journal-title":"Psychopharmacol (Berl)"},{"key":"2249_CR85","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hup.596","volume":"19","author":"JV Baranski","year":"2004","unstructured":"Baranski JV, Pigeau R, Dinich P, Jacobs I. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol Clin Exp. 2004;19:323\u201332.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"2249_CR86","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3357\/ASEM.3212.2012","volume":"83","author":"AM Kelley","year":"2012","unstructured":"Kelley AM, Webb CM, Athy JR, Ley S, Gaydos S. Cognition enhancement by modafinil: a meta-analysis. Aviat Space Environ Med. 2012;83:685\u201390.","journal-title":"Aviat Space Environ Med"},{"key":"2249_CR87","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00213-002-1166-3","volume":"163","author":"JH Meyer","year":"2002","unstructured":"Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacol (Berl). 2002;163:102\u20135.","journal-title":"Psychopharmacol (Berl)"},{"key":"2249_CR88","doi-asserted-by":"publisher","first-page":"e25790","DOI":"10.1371\/journal.pone.0025790","volume":"6","author":"KC Schmitt","year":"2011","unstructured":"Schmitt KC, Reith MEA. The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PLoS One. 2011;6:e25790.","journal-title":"PLoS One"},{"key":"2249_CR89","first-page":"349","volume":"3","author":"P Gerrard","year":"2007","unstructured":"Gerrard P, Malcolm R. Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007;3:349\u201364.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2249_CR90","doi-asserted-by":"publisher","first-page":"173073","DOI":"10.1016\/j.pbb.2020.173073","volume":"200","author":"S Tafseer","year":"2021","unstructured":"Tafseer S, Gupta R, Ahmad R, Jain S, Bhatia MS, Gupta LK. Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder. Pharm Biochem Behav. 2021;200:173073.","journal-title":"Pharm Biochem Behav"},{"key":"2249_CR91","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/03602532.2019.1620763","volume":"51","author":"R Costa","year":"2019","unstructured":"Costa R, Oliveira NG, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects. Drug Metab Rev. 2019;51:293\u2013313.","journal-title":"Drug Metab Rev"},{"key":"2249_CR92","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2174\/092986712799462649","volume":"19","author":"AK Rahn","year":"2012","unstructured":"Rahn AK, Slusher SB, Kaplin IA. Glutamate in CNS neurodegeneration and cognition and its regulation by GCPII inhibition. Curr Med Chem. 2012;19:1335\u201345.","journal-title":"Curr Med Chem"},{"key":"2249_CR93","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev-neuro-071714-033821","volume":"38","author":"L Volk","year":"2015","unstructured":"Volk L, Chiu S-L, Sharma K, Huganir RL. Glutamate synapses in human cognitive disorders. Annu Rev Neurosci. 2015;38:127\u201349.","journal-title":"Annu Rev Neurosci"},{"key":"2249_CR94","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neuropharm.2011.08.044","volume":"62","author":"RS Duman","year":"2012","unstructured":"Duman RS, Li N, Liu R-J, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012;62:35\u201341.","journal-title":"Neuropharmacology"},{"key":"2249_CR95","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","volume":"25","author":"M Fava","year":"2020","unstructured":"Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020;25:1592\u2013603.","journal-title":"Mol Psychiatry"},{"key":"2249_CR96","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/JCP.0000000000000960","volume":"38","author":"S Vidal","year":"2018","unstructured":"Vidal S, Gex-Fabry M, Bancila V, Michalopoulos G, Warrot D, Jermann F, et al. Efficacy and safety of a rapid intravenous injection of ketamine 0.5 mg\/kg in treatment-resistant major depression: an open 4-week longitudinal study. J Clin Psychopharmacol. 2018;38:590\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"2249_CR97","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.neubiorev.2020.11.020","volume":"120","author":"H Gill","year":"2021","unstructured":"Gill H, Gill B, Rodrigues NB, Lipsitz O, Rosenblat JD, El-Halabi S, et al. The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research. Neurosci Biobehav Rev. 2021;120:78\u201385.","journal-title":"Neurosci Biobehav Rev"},{"key":"2249_CR98","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1017\/S1461145714001011","volume":"17","author":"PR Shiroma","year":"2014","unstructured":"Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17:1805\u201313.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2249_CR99","doi-asserted-by":"crossref","unstructured":"Stippl A, Scheidegger M, Aust S, Herrera A, Bajbouj M, G\u00e4rtner M, et al. Ketamine specifically reduces cognitive symptoms in depressed patients: An investigation of associated neural activation patterns. J Psychiatr Res. 2021;136:402\u201308.","DOI":"10.1016\/j.jpsychires.2021.02.028"},{"key":"2249_CR100","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fpsyt.2016.00047","volume":"7","author":"MWB Zhang","year":"2016","unstructured":"Zhang MWB, Ho R. Controversies of the effect of ketamine on cognition. Front Psychiatry. 2016;7:47.","journal-title":"Front Psychiatry"},{"key":"2249_CR101","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/JCP.0000000000000441","volume":"36","author":"Y Lee","year":"2016","unstructured":"Lee Y, Syeda K, Maruschak NA, Cha DS, Mansur RB, Wium-Andersen IK, et al. A new perspective on the anti-suicide effects with ketamine treatment: a procognitive effect. J Clin Psychopharmacol. 2016;36:50\u201356.","journal-title":"J Clin Psychopharmacol"},{"key":"2249_CR102","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s41386-020-0644-9","volume":"45","author":"CG Abdallah","year":"2020","unstructured":"Abdallah CG, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, et al. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology 2020;45:990\u20137.","journal-title":"Neuropsychopharmacology"},{"key":"2249_CR103","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jad.2019.03.075","volume":"251","author":"M-H Chen","year":"2019","unstructured":"Chen M-H, Lin W-C, Wu H-J, Cheng C-M, Li C-T, Hong C-J, et al. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD). J Affect Disord. 2019;251:162\u20139.","journal-title":"J Affect Disord"},{"key":"2249_CR104","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pharmthera.2018.05.010","volume":"190","author":"CG Abdallah","year":"2018","unstructured":"Abdallah CG, Sanacora G, Duman RS, Krystal JH. The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? Pharm Ther. 2018;190:148\u201358.","journal-title":"Pharm Ther"},{"key":"2249_CR105","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jad.2020.08.058","volume":"277","author":"PR Shiroma","year":"2020","unstructured":"Shiroma PR, Thuras P, Wels J, Albott CS, Erbes C, Tye S, et al. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord. 2020;277:470\u20137.","journal-title":"J Affect Disord"},{"key":"2249_CR106","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/npp.2014.298","volume":"40","author":"JW Murrough","year":"2015","unstructured":"Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, et al. Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial. Neuropsychopharmacology 2015;40:1084\u201390.","journal-title":"Neuropsychopharmacology"},{"key":"2249_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2019.08.012","volume":"259","author":"W Liu","year":"2019","unstructured":"Liu W, Zhou Y, Zheng W, Wang C, Zhan Y, Lan X, et al. Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression. J Affect Disord. 2019;259:1\u20136.","journal-title":"J Affect Disord"},{"key":"2249_CR108","doi-asserted-by":"publisher","first-page":"113993","DOI":"10.1016\/j.psychres.2021.113993","volume":"302","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Rodrigues NB, Lipsitz O, Chen-Li D, Lee JG, et al. The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE). Psychiatry Res. 2021;302:113993.","journal-title":"Psychiatry Res"},{"key":"2249_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2018.07.033","volume":"241","author":"M-H Chen","year":"2018","unstructured":"Chen M-H, Li C-T, Lin W-C, Hong C-J, Tu P-C, Bai Y-M, et al. Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion. J Affect Disord. 2018;241:1\u20137.","journal-title":"J Affect Disord"},{"key":"2249_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01327-5","volume":"11","author":"MT Davis","year":"2021","unstructured":"Davis MT, DellaGiogia N, Maruff P, Pietrzak RH, Esterlis I. Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder. Transl Psychiatry. 2021;11:205.","journal-title":"Transl Psychiatry"},{"key":"2249_CR111","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0893-133X(95)00137-3","volume":"14","author":"AK Malhotra","year":"1996","unstructured":"Malhotra AK, Pinals DA, Weingartner H, Sirocco K, David Missar C, Pickar D, et al. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996;14:301\u20137.","journal-title":"Neuropsychopharmacology"},{"key":"2249_CR112","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/026988119601000208","volume":"10","author":"GC Harborne","year":"1996","unstructured":"Harborne GC, Watson FL, Healy DT, Groves L. The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. J Psychopharmacol. 1996;10:134\u201340.","journal-title":"J Psychopharmacol"},{"key":"2249_CR113","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/sj.npp.1300342","volume":"29","author":"CJA Morgan","year":"2004","unstructured":"Morgan CJA, Mofeez A, Brandner B, Bromley L, Curran HV. Acute Effects of Ketamine on Memory Systems and Psychotic Symptoms in Healthy Volunteers. Neuropsychopharmacology 2004;29:208\u201318.","journal-title":"Neuropsychopharmacology"},{"key":"2249_CR114","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s002130000511","volume":"152","author":"LAB Hetem","year":"2000","unstructured":"Hetem LAB, Danion JM, Diemunsch P, Brandt C. Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacol (Berl). 2000;152:283\u20138.","journal-title":"Psychopharmacol (Berl)"},{"key":"2249_CR115","first-page":"298","volume":"172","author":"CJA Morgan","year":"2004","unstructured":"Morgan CJA, Mofeez A, Brandner B, Bromley L, Curran HV. Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose\u2013response study. Psychopharmacol (Berl). 2004;172:298\u2013308.","journal-title":"Psychopharmacol (Berl)"},{"key":"2249_CR116","doi-asserted-by":"publisher","unstructured":"Mkrtchian A, Evans JW, Kraus C, Yuan P, Kadriu B, Nugent AC, et al. Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. Mol Psychiatry. 2020. 2020. https:\/\/doi.org\/10.1038\/s41380-020-00878-1.","DOI":"10.1038\/s41380-020-00878-1"},{"key":"2249_CR117","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jad.2019.06.065","volume":"258","author":"H Sakurai","year":"2019","unstructured":"Sakurai H, Dording C, Yeung A, Foster S, Jain F, Chang T, et al. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. J Affect Disord. 2019;258:102\u20138.","journal-title":"J Affect Disord"},{"key":"2249_CR118","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1038\/npp.2017.106","volume":"42","author":"SJ Mathew","year":"2017","unstructured":"Mathew SJ, Gueorguieva R, Brandt C, Fava M, Sanacora G. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology 2017;42:2567\u201374.","journal-title":"Neuropsychopharmacology"},{"key":"2249_CR119","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jagp.2019.08.011","volume":"28","author":"H Lavretsky","year":"2020","unstructured":"Lavretsky H, Laird KT, Krause-Sorio B, Heimberg BF, Yeargin J, Grzenda A, et al. A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints. Am J Geriatr Psychiatry. 2020;28:178\u201390.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2249_CR120","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/gps.2813","volume":"27","author":"EJ Lenze","year":"2012","unstructured":"Lenze EJ, Skidmore ER, Begley AE, Newcomer JW, Butters MA, Whyte EM. Memantine for late\u2010life depression and apathy after a disabling medical event: a 12\u2010week, double\u2010blind placebo\u2010controlled pilot study. Int J Geriatr Psychiatry. 2012;27:974\u201380.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2249_CR121","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3233\/JAD-161251","volume":"57","author":"T Kishi","year":"2017","unstructured":"Kishi T, Matsunaga S, Iwata N. A meta-analysis of memantine for depression. J Alzheimer\u2019s Dis. 2017;57:113\u201321.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"2249_CR122","doi-asserted-by":"publisher","first-page":"0","DOI":"10.4088\/JCP.v69n0308","volume":"69","author":"LH Muhonen","year":"2008","unstructured":"Muhonen LH, L\u00f6nnqvist J, Juva K, Alho H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry. 2008;69:0.","journal-title":"J Clin Psychiatry"},{"key":"2249_CR123","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1177\/0269881112458728","volume":"26","author":"KR Nations","year":"2012","unstructured":"Nations KR, Dogterom P, Bursi R, Schipper J, Greenwald S, Zraket D, et al. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial. J Psychopharmacol. 2012;26:1525\u201339.","journal-title":"J Psychopharmacol"},{"key":"2249_CR124","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/1570159X14666160321123221","volume":"15","author":"BA Jaso","year":"2017","unstructured":"Jaso BA, Niciu MJ, Iadarola ND, Lally N, Richards EM, Park M, et al. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder. Curr Neuropharmacol. 2017;15:57\u201370.","journal-title":"Curr Neuropharmacol"},{"key":"2249_CR125","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/sj.npp.1301257","volume":"32","author":"E Wezenberg","year":"2007","unstructured":"Wezenberg E, Verkes RJ, Ruigt GSF, Hulstijn W, Sabbe BGC. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology 2007;32:1272\u201383.","journal-title":"Neuropsychopharmacology"},{"key":"2249_CR126","doi-asserted-by":"crossref","unstructured":"Carvalho FA, Miskowiak KK, Hyphantis NT, Kohler AC, Alves SG, Bortolato B. et al. Cognitive dysfunction in depression\u2013pathophysiology and novel targets. CNS Neurol Disord Targets (Formerly Curr Drug Targets-CNS Neurol Disord. 2014;13:1819\u201335..","DOI":"10.2174\/1871527313666141130203627"},{"key":"2249_CR127","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11011-018-0326-z","volume":"34","author":"Q Xia","year":"2019","unstructured":"Xia Q, Wang H, Yin H, Yang Z. Excessive corticosterone induces excitotoxicity of hippocampal neurons and sensitivity of potassium channels via insulin-signaling pathway. Metab Brain Dis. 2019;34:119\u201328.","journal-title":"Metab Brain Dis"},{"key":"2249_CR128","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1523\/JNEUROSCI.18-17-06662.1998","volume":"18","author":"Y Sagara","year":"1998","unstructured":"Sagara Y, Schubert D. The activation of metabotropic glutamate receptors protects nerve cells from oxidative stress. J Neurosci. 1998;18:6662\u201371.","journal-title":"J Neurosci"},{"key":"2249_CR129","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/13543776.2021.1903431","volume":"31","author":"AM Qunies","year":"2021","unstructured":"Qunies AM, Emmitte KA. Negative allosteric modulators of group II metabotropic glutamate receptors: A patent review (2015 \u2013 present). Expert Opin Ther Pat. 2021;31:687\u2013708.","journal-title":"Expert Opin Ther Pat"},{"key":"2249_CR130","doi-asserted-by":"publisher","first-page":"0","DOI":"10.4088\/JCP.18m12470","volume":"81","author":"D Umbricht","year":"2020","unstructured":"Umbricht D, Niggli M, Sanwald-Ducray P, Deptula D, Moore R, Gr\u00fcnbauer W, et al. Randomized, double-blind, placebo-controlled trial of the mGlu2\/3 negative allosteric modulator decoglurant in partially refractory major depressive disorder. J Clin Psychiatry. 2020;81:0.","journal-title":"J Clin Psychiatry"},{"key":"2249_CR131","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2174\/1381612023396582","volume":"8","author":"F Gualtieri","year":"2002","unstructured":"Gualtieri F, Manetti D, Romanelli M, Ghelardini C. Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Des. 2002;8:125\u201338.","journal-title":"Curr Pharm Des"},{"key":"2249_CR132","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.pneurobio.2011.06.002","volume":"94","author":"P Bentley","year":"2011","unstructured":"Bentley P, Driver J, Dolan RJ. Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging. Prog Neurobiol. 2011;94:360\u201388.","journal-title":"Prog Neurobiol"},{"key":"2249_CR133","first-page":"17","volume":"9","author":"R Conant","year":"2004","unstructured":"Conant R, Schauss AG. Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature. Alter Med Rev. 2004;9:17\u201331.","journal-title":"Alter Med Rev"},{"key":"2249_CR134","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/JEP.S35326","volume":"4","author":"L Colucci","year":"2012","unstructured":"Colucci L, Bosco M, Rosario Ziello A, Rea R, Amenta F, Fasanaro AM. Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review. J Exp Pharm. 2012;4:163\u201372.","journal-title":"J Exp Pharm"},{"key":"2249_CR135","doi-asserted-by":"crossref","unstructured":"Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP\u2010choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;2004:CD000269.","DOI":"10.1002\/14651858.CD000269.pub2"},{"key":"2249_CR136","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.04.010","volume":"25","author":"JJ Secades","year":"2016","unstructured":"Secades JJ, Alvarez-Sab\u00edn J, Castillo J, D\u00edez-Tejedor E, Mart\u00ednez-Vila E, R\u00edos J, et al. Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. J Stroke Cerebrovasc Dis. 2016;25:1984\u201396.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2249_CR137","first-page":"41","volume":"9","author":"A Meshkini","year":"2017","unstructured":"Meshkini A, Meshkini M, Sadeghi-Bazargani H. Citicoline for traumatic brain injury: a systematic review & meta-analysis. J Inj Violence Res. 2017;9:41.","journal-title":"J Inj Violence Res"},{"key":"2249_CR138","doi-asserted-by":"publisher","first-page":"620119","DOI":"10.3389\/fnbeh.2020.620119","volume":"14","author":"PJ Fitzgerald","year":"2021","unstructured":"Fitzgerald PJ, Hale PJ, Ghimire A, Watson BO. Repurposing Cholinesterase Inhibitors as Antidepressants? Dose and Stress-Sensitivity May Be Critical to Opening Possibilities. Front Behav Neurosci. 2021;14:620119.","journal-title":"Front Behav Neurosci"},{"key":"2249_CR139","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11920-000-0005-7","volume":"2","author":"T Burt","year":"2000","unstructured":"Burt T. Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents. Curr Psychiatry Rep. 2000;2:473\u20138.","journal-title":"Curr Psychiatry Rep"},{"key":"2249_CR140","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/archgenpsychiatry.2010.184","volume":"68","author":"CF Reynolds III","year":"2011","unstructured":"Reynolds CF III, Butters MA, Lopez O, Pollock BG, Dew MA, Mulsant BH, et al. Maintenance Treatment of Depression in Old Age: A Randomized, Double-blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Combined With Antidepressant Pharmacotherapy. Arch Gen Psychiatry. 2011;68:51\u201360.","journal-title":"Arch Gen Psychiatry"},{"key":"2249_CR141","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/gps.1958","volume":"23","author":"GH Pelton","year":"2008","unstructured":"Pelton GH, Harper OL, Tabert MH, Sackeim HA, Scarmeas N, Roose SP, et al. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Int J Geriatr Psychiatry. 2008;23:670\u20136.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2249_CR142","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.jagp.2018.05.008","volume":"26","author":"DP Devanand","year":"2018","unstructured":"Devanand DP, Pelton GH, D\u2019Antonio K, Ciarleglio A, Scodes J, Andrews H, et al. Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial. Am J Geriatr Psychiatry. 2018;26:1050\u201360.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2249_CR143","first-page":"448","volume":"19","author":"RC Mohs","year":"1983","unstructured":"Mohs RC. The Alzheimer\u2019s disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983;19:448\u201350.","journal-title":"Psychopharmacol Bull"},{"key":"2249_CR144","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/ane.12153","volume":"129","author":"A Karin","year":"2014","unstructured":"Karin A, Hannesdottir K, Jaeger J, Annas P, Segerdahl M, Karlsson P, et al. Psychometric evaluation of ADAS\u2010C og and NTB for measuring drug response. Acta Neurol Scand. 2014;129:114\u201322.","journal-title":"Acta Neurol Scand"},{"key":"2249_CR145","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/WNN.0b013e3181799df1","volume":"21","author":"DB FitzGerald","year":"2008","unstructured":"FitzGerald DB, Crucian GP, Mielke JB, Shenal BV, Burks D, Womack KB, et al. Effects of donepezil on verbal memory after semantic processing in healthy older adults. Cogn Behav Neurol. 2008;21:57\u201364.","journal-title":"Cogn Behav Neurol"},{"key":"2249_CR146","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/hup.1044","volume":"24","author":"ALC Zaninotto","year":"2009","unstructured":"Zaninotto ALC, Bueno OFA, Pradella\u2010Hallinan M, Tufik S, Rusted J, Stough C, et al. Acute cognitive effects of donepezil in young, healthy volunteers. Hum Psychopharmacol Clin Exp. 2009;24:453\u201364.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"2249_CR147","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/0269881104040248","volume":"18","author":"LJ Beglinger","year":"2004","unstructured":"Beglinger LJ, Gaydos BL, Kareken DA, Tangphao-Daniels O, Siemers ER, Mohs RC. Neuropsychological test performance in healthy volunteers before and after donepezil administration. J Psychopharmacol. 2004;18:102\u20138.","journal-title":"J Psychopharmacol"},{"key":"2249_CR148","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/01.jcp.0000155822.51962.b4","volume":"25","author":"LJ Beglinger","year":"2005","unstructured":"Beglinger LJ, Tangphao-Daniels O, Kareken DA, Zhang L, Mohs R, Siemers ER. Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: a randomized, controlled study. J Clin Psychopharmacol. 2005;25:159\u201365.","journal-title":"J Clin Psychopharmacol"},{"key":"2249_CR149","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/gps.1951","volume":"23","author":"PE Holtzheimer III","year":"2008","unstructured":"Holtzheimer PE III, Meeks TW, Kelley ME, Mufti M, Young R, McWhorter K, et al. A double blind, placebo\u2010controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int J Geriatr Psychiatry A J Psychiatry Late Life Allied Sci. 2008;23:625\u201331.","journal-title":"Int J Geriatr Psychiatry A J Psychiatry Late Life Allied Sci"},{"key":"2249_CR150","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/156720509787602861","volume":"6","author":"G Pepeu","year":"2009","unstructured":"Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res. 2009;6:86\u201396.","journal-title":"Curr Alzheimer Res"},{"key":"2249_CR151","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pharmthera.2009.07.001","volume":"124","author":"T Maurice","year":"2009","unstructured":"Maurice T, Su T-P. The pharmacology of sigma-1 receptors. Pharm Ther. 2009;124:195\u2013206.","journal-title":"Pharm Ther"},{"key":"2249_CR152","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.pbb.2006.07.009","volume":"84","author":"T Maurice","year":"2006","unstructured":"Maurice T, Gr\u00e9goire C, Espallergues J. Neuro (active) steroids actions at the neuromodulatory sigma1 (\u03c31) receptor: biochemical and physiological evidences, consequences in neuroprotection. Pharm Biochem Behav. 2006;84:581\u201397.","journal-title":"Pharm Biochem Behav"},{"key":"2249_CR153","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3389\/fnins.2019.00862","volume":"13","author":"DA Ryskamp","year":"2019","unstructured":"Ryskamp DA, Korban S, Zhemkov V, Kraskovskaya N, Bezprozvanny I. Neuronal sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases. Front Neurosci. 2019;13:862.","journal-title":"Front Neurosci"},{"key":"2249_CR154","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2018.01.009","volume":"186","author":"DO Sambo","year":"2018","unstructured":"Sambo DO, Lebowitz JJ, Khoshbouei H. The sigma-1 receptor as a regulator of dopamine neurotransmission: a potential therapeutic target for methamphetamine addiction. Pharm Ther. 2018;186:152\u201367.","journal-title":"Pharm Ther"},{"key":"2249_CR155","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.2174\/0929867033456783","volume":"10","author":"T-P Su","year":"2003","unstructured":"Su T-P, Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem. 2003;10:2073\u201380.","journal-title":"Curr Med Chem"},{"key":"2249_CR156","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1017\/S003329170300758X","volume":"33","author":"OP Almeida","year":"2003","unstructured":"Almeida OP, Burton EJ, Ferrier N, McKeith IG, O\u2019Brien JT. Depression with late onset is associated with right frontal lobe atrophy. Psychol Med. 2003;33:675\u201381.","journal-title":"Psychol Med"},{"key":"2249_CR157","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0006-3223(00)00971-9","volume":"48","author":"RM Sapolsky","year":"2000","unstructured":"Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry. 2000;48:755\u201365.","journal-title":"Biol Psychiatry"},{"key":"2249_CR158","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1001\/archpsyc.57.10.925","volume":"57","author":"RM Sapolsky","year":"2000","unstructured":"Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry. 2000;57:925\u201335.","journal-title":"Arch Gen Psychiatry"},{"key":"2249_CR159","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0006-3223(00)00994-X","volume":"48","author":"YI Sheline","year":"2000","unstructured":"Sheline YI. 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biol Psychiatry. 2000;48:791\u2013800.","journal-title":"Biol Psychiatry"},{"key":"2249_CR160","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1073\/pnas.93.9.3908","volume":"93","author":"YI Sheline","year":"1996","unstructured":"Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci. 1996;93:3908\u201313.","journal-title":"Proc Natl Acad Sci"},{"key":"2249_CR161","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1097\/00001756-199806220-00021","volume":"9","author":"YI Sheline","year":"1998","unstructured":"Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport 1998;9:2023\u20138.","journal-title":"Neuroreport"},{"key":"2249_CR162","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/nn1971","volume":"10","author":"K Martinowich","year":"2007","unstructured":"Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci. 2007;10:1089\u201393.","journal-title":"Nat Neurosci"},{"key":"2249_CR163","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/14728222.2020.1846720","volume":"24","author":"AS de Miranda","year":"2020","unstructured":"de Miranda AS, de Barros JLVM, Teixeira AL. Is neurotrophin-3 (NT-3): a potential therapeutic target for depression and anxiety? Expert Opin Ther Targets. 2020;24:1225\u201338.","journal-title":"Expert Opin Ther Targets"},{"key":"2249_CR164","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/hup.609","volume":"19","author":"SM O\u2019Brien","year":"2004","unstructured":"O\u2019Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol Clin Exp. 2004;19:397\u2013403.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"2249_CR165","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.neubiorev.2012.10.005","volume":"37","author":"CF Zorumski","year":"2013","unstructured":"Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S. Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev. 2013;37:109\u201322.","journal-title":"Neurosci Biobehav Rev"},{"key":"2249_CR166","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3390\/ijms22041758","volume":"22","author":"FB Almeida","year":"2021","unstructured":"Almeida FB, Barros HMT, Pinna G. Neurosteroids and Neurotrophic Factors: What Is Their Promise as Biomarkers for Major Depression and PTSD? Int J Mol Sci. 2021;22:1758.","journal-title":"Int J Mol Sci"},{"key":"2249_CR167","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fpsyg.2011.00159","volume":"2","author":"P Andrews","year":"2011","unstructured":"Andrews P, Kornstein S, Halberstadt L, Gardner C, Neale MC. Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol. 2011;2:159.","journal-title":"Front Psychol"},{"key":"2249_CR168","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1017\/S1461145704004080","volume":"7","author":"DA Morilak","year":"2004","unstructured":"Morilak DA, Frazer A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol. 2004;7:193\u2013218.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2249_CR169","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1074\/jbc.RA118.005543","volume":"294","author":"S Murugan","year":"2019","unstructured":"Murugan S, Jakka P, Namani S, Mujumdar V, Radhakrishnan G. The neurosteroid pregnenolone promotes degradation of key proteins in the innate immune signaling to suppress inflammation. J Biol Chem. 2019;294:4596\u2013607.","journal-title":"J Biol Chem"},{"key":"2249_CR170","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1517\/13543784.2011.594039","volume":"20","author":"J Prins","year":"2011","unstructured":"Prins J, Olivier B, Korte SM. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opin Investig Drugs. 2011;20:1107\u201330.","journal-title":"Expert Opin Investig Drugs"},{"key":"2249_CR171","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.neuropharm.2005.10.015","volume":"50","author":"L Chen","year":"2006","unstructured":"Chen L, Dai X-N, Sokabe M. Chronic administration of dehydroepiandrosterone sulfate (DHEAS) primes for facilitated induction of long-term potentiation via sigma 1 (\u03c31) receptor: optical imaging study in rat hippocampal slices. Neuropharmacology 2006;50:380\u201392.","journal-title":"Neuropharmacology"},{"key":"2249_CR172","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1017\/S1461145707008334","volume":"11","author":"Z-M Wang","year":"2008","unstructured":"Wang Z-M, Qi Y-J, Wu P-Y, Zhu Y, Dong Y-L, Cheng Z-X, et al. Neuroactive steroid pregnenolone sulphate inhibits long-term potentiation via activation of \u03b12-adrenoreceptors at excitatory synapses in rat medial prefrontal cortex. Int J Neuropsychopharmacol. 2008;11:611\u201324.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2249_CR173","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/hipo.20273","volume":"17","author":"J Sabeti","year":"2007","unstructured":"Sabeti J, Nelson TE, Purdy RH, Gruol DL. Steroid pregnenolone sulfate enhances NMDA\u2010receptor\u2010independent long\u2010term potentiation at hippocampal CA1 synapses: Role for L\u2010type calcium channels and sigma\u2010receptors. Hippocampus 2007;17:349\u201369.","journal-title":"Hippocampus"},{"key":"2249_CR174","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0006-3223(96)00043-1","volume":"41","author":"OM Wolkowitz","year":"1997","unstructured":"Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Raum WJ, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry. 1997;41:311\u20138.","journal-title":"Biol Psychiatry"},{"key":"2249_CR175","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1749-6632.1995.tb17403.x-i1","volume":"774","author":"OM Wolkowitz","year":"1995","unstructured":"Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Ormiston S, et al. Antidepressant and cognition\u2010enhancing effects of DHEA in major depression. Ann N. Y Acad Sci. 1995;774:337\u20139.","journal-title":"Ann N. Y Acad Sci"},{"key":"2249_CR176","unstructured":"Evans JG, Malouf R, Huppert FAH, Van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. Cochrane Database Syst Rev. 2006;2006:CD006221."},{"key":"2249_CR177","doi-asserted-by":"crossref","unstructured":"Huppert FAH, Van Niekerk J. Dehydroepiandrosterone (DHEA) supplementation for cognitive function. Cochrane Database Syst Rev. 2001:CD000304.","DOI":"10.1002\/14651858.CD000304"},{"key":"2249_CR178","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00213-005-0136-y","volume":"188","author":"HA Alhaj","year":"2006","unstructured":"Alhaj HA, Massey AE, McAllister-Williams RH. Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a double-blind, placebo-controlled study. Psychopharmacol (Berl). 2006;188:541\u201351.","journal-title":"Psychopharmacol (Berl)"},{"key":"2249_CR179","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/hup.1106","volume":"25","author":"I Hindmarch","year":"2010","unstructured":"Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol. 2010;25:193\u2013200.","journal-title":"Hum Psychopharmacol"},{"key":"2249_CR180","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.biopsych.2007.04.001","volume":"62","author":"M Ishikawa","year":"2007","unstructured":"Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C] SA4503. Biol Psychiatry. 2007;62:878\u201383.","journal-title":"Biol Psychiatry"},{"key":"2249_CR181","first-page":"139","volume":"8","author":"S la Pia","year":"1992","unstructured":"la Pia S, Giorgio D, Ciriello R, Sannino A. Double blind controlled study to evaluate the effectiveness and tolerability of fluoxetine versus mianserin in the treatment of depressive disorders among the elderly and their effects on cognitive-behavioral parameters. N. Trends Exp Clin Psychiatry. 1992;8:139\u201346. al et","journal-title":"N. Trends Exp Clin Psychiatry"},{"key":"2249_CR182","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1185\/03007999009111652","volume":"12","author":"A Perez","year":"1990","unstructured":"Perez A, Ashford JJ. A double-blind, randomized comparison of fluvoxamine with mianserin in depressive illness. Curr Med Res Opin. 1990;12:234\u201341.","journal-title":"Curr Med Res Opin"},{"key":"2249_CR183","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/BF00174375","volume":"89","author":"HV Curran","year":"1986","unstructured":"Curran HV, Shine P, Lader M. Effects of repeated doses of fluvoxamine, mianserin and placebo on memory and measures of sedation. Psychopharmacol (Berl). 1986;89:360\u20133.","journal-title":"Psychopharmacol (Berl)"},{"key":"2249_CR184","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/j.1440-1819.2006.01564.x","volume":"60","author":"L Mandelli","year":"2006","unstructured":"Mandelli L, Serretti A, Colombo C, Florita M, Santoro A, Rossini D, et al. Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis. Psychiatry Clin Neurosci. 2006;60:598\u2013604.","journal-title":"Psychiatry Clin Neurosci"},{"key":"2249_CR185","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0031-9384(98)00256-X","volume":"66","author":"CA Frye","year":"1999","unstructured":"Frye CA, Lacey EH. The Neurosteroids DHEA and DHEAS May Influence Cognitive Performance by Altering Affective State. Physiol Behav. 1999;66:85\u201392.","journal-title":"Physiol Behav"},{"key":"2249_CR186","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.psyneuen.2018.09.010","volume":"105","author":"K Wingenfeld","year":"2019","unstructured":"Wingenfeld K, Otte C. Mineralocorticoid receptor function and cognition in health and disease. Psychoneuroendocrinology 2019;105:25\u201335.","journal-title":"Psychoneuroendocrinology"},{"key":"2249_CR187","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/npp.2014.181","volume":"40","author":"C Otte","year":"2015","unstructured":"Otte C, Wingenfeld K, Kuehl LK, Kaczmarczyk M, Richter S, Quante A, et al. Mineralocorticoid Receptor Stimulation Improves Cognitive Function and Decreases Cortisol Secretion in Depressed Patients and Healthy Individuals. Neuropsychopharmacology 2015;40:386\u201393.","journal-title":"Neuropsychopharmacology"},{"key":"2249_CR188","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jpsychires.2015.08.001","volume":"69","author":"C Otte","year":"2015","unstructured":"Otte C, Wingenfeld K, Kuehl LK, Richter S, Regen F, Piber D, et al. Cognitive function in older adults with major depression: Effects of mineralocorticoid receptor stimulation. J Psychiatr Res. 2015;69:120\u20135.","journal-title":"J Psychiatr Res"},{"key":"2249_CR189","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jpsychires.2015.04.024","volume":"68","author":"SD Targum","year":"2015","unstructured":"Targum SD, Wedel PC, Fava M. Changes in cognitive symptoms after a buspirone\u2013melatonin combination treatment for Major Depressive Disorder. J Psychiatr Res. 2015;68:392\u20136.","journal-title":"J Psychiatr Res"},{"key":"2249_CR190","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1210\/jc.2015-1859","volume":"100","author":"K Obayashi","year":"2015","unstructured":"Obayashi K, Saeki K, Iwamoto J, Tone N, Tanaka K, Kataoka H, et al. Physiological levels of melatonin relate to cognitive function and depressive symptoms: the HEIJO-KYO cohort. J Clin Endocrinol Metab. 2015;100:3090\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"2249_CR191","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/npp.2013.335","volume":"39","author":"KW Miskowiak","year":"2014","unstructured":"Miskowiak KW, Vinberg M, Christensen EM, Bukh JD, Harmer CJ, Ehrenreich H, et al. Recombinant Human Erythropoietin for Treating Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial. Neuropsychopharmacology 2014;39:1399\u2013408.","journal-title":"Neuropsychopharmacology"},{"key":"2249_CR192","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.euroneuro.2016.05.009","volume":"26","author":"CV Ott","year":"2016","unstructured":"Ott CV, Vinberg M, Kessing LV, Miskowiak KW. The effect of erythropoietin on cognition in affective disorders \u2013 Associations with baseline deficits and change in subjective cognitive complaints. Eur Neuropsychopharmacol. 2016;26:1264\u201373.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2249_CR193","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00221-007-1102-1","volume":"184","author":"K Miskowiak","year":"2008","unstructured":"Miskowiak K, Inkster B, O\u2019Sullivan U, Selvaraj S, Goodwin GM, Harmer CJ. Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Exp Brain Res. 2008;184:313\u201321.","journal-title":"Exp Brain Res"},{"key":"2249_CR194","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1523\/JNEUROSCI.5013-06.2007","volume":"27","author":"K Miskowiak","year":"2007","unstructured":"Miskowiak K, O\u2019Sullivan U, Harmer CJ. Erythropoietin enhances hippocampal response during memory retrieval in humans. J Neurosci. 2007;27:2788\u201392.","journal-title":"J Neurosci"},{"key":"2249_CR195","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1741-7007-6-37","volume":"6","author":"B Adamcio","year":"2008","unstructured":"Adamcio B, Sargin D, Stradomska A, Medrihan L, Gertler C, Theis F, et al. Erythropoietin enhances hippocampal long-term potentiation and memory. BMC Biol. 2008;6:1\u201316.","journal-title":"BMC Biol"},{"key":"2249_CR196","doi-asserted-by":"publisher","first-page":"102666","DOI":"10.1016\/j.amsu.2021.102666","volume":"69","author":"MF Said","year":"2021","unstructured":"Said MF, Islam AA, Massi MN, Prihantono. Effect of erythropoietin administration on the expression of brain-derived neurotrophic factor, stromal cell-derived Factor-1, and neuron-specific enolase in traumatic brain injury: A literature review. Ann Med Surg. 2021;69:102666.","journal-title":"Ann Med Surg"},{"key":"2249_CR197","doi-asserted-by":"publisher","first-page":"e0127629","DOI":"10.1371\/journal.pone.0127629","volume":"10","author":"M Vinberg","year":"2015","unstructured":"Vinberg M, Miskowiak K, Hoejman P, Pedersen M, Kessing LV. The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study. PLoS One. 2015;10:e0127629.","journal-title":"PLoS One"},{"key":"2249_CR198","first-page":"0","volume":"74","author":"D Mischoulon","year":"2013","unstructured":"Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Baer L, et al. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry. 2013;74:0.","journal-title":"J Clin Psychiatry"},{"key":"2249_CR199","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-020-00298-z","volume":"19","author":"A Cuomo","year":"2020","unstructured":"Cuomo A, Beccarini Crescenzi B, Bolognesi S, Goracci A, Koukouna D, Rossi R, et al. S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review. Ann Gen Psychiatry. 2020;19:50.","journal-title":"Ann Gen Psychiatry"},{"key":"2249_CR200","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/brainsci10090600","volume":"10","author":"ND Sachinvala","year":"2020","unstructured":"Sachinvala ND, Teramoto N, Stergiou A. Proposed neuroimmune roles of dimethyl fumarate, bupropion, S-adenosylmethionine, and vitamin D3 in affording a chronically Ill patient sustained relief from inflammation and major depression. Brain Sci. 2020;10:600.","journal-title":"Brain Sci"},{"key":"2249_CR201","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.eurpsy.2011.03.006","volume":"27","author":"Y Levkovitz","year":"2012","unstructured":"Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Eur Psychiatry. 2012;27:518\u201321.","journal-title":"Eur Psychiatry"},{"key":"2249_CR202","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s42003-022-03280-5","volume":"5","author":"K Fukumoto","year":"2022","unstructured":"Fukumoto K, Ito K, Saer B, Taylor G, Ye S, Yamano M, et al. Excess S-adenosylmethionine inhibits methylation via catabolism to adenine. Commun Biol. 2022;5:313.","journal-title":"Commun Biol"},{"key":"2249_CR203","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40263-015-0263-x","volume":"29","author":"RS McIntyre","year":"2015","unstructured":"McIntyre RS, Xiao HX, Syeda K, Vinberg M, Carvalho AF, Mansur RB, et al. The Prevalence, Measurement, and Treatment of the Cognitive Dimension\/Domain in Major Depressive Disorder. CNS Drugs. 2015;29:577\u201389.","journal-title":"CNS Drugs"},{"key":"2249_CR204","first-page":"9","volume":"18","author":"JM Ferguson","year":"2003","unstructured":"Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol. 2003;18:9\u201314.","journal-title":"Int Clin Psychopharmacol"},{"key":"2249_CR205","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.05.010","volume":"103","author":"L Gong","year":"2018","unstructured":"Gong L, He C, Zhang H, Zhang H, Zhang Z, Xie C. Disrupted reward and cognitive control networks contribute to anhedonia in depression. J Psychiatr Res. 2018;103:61\u201368.","journal-title":"J Psychiatr Res"},{"key":"2249_CR206","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.euroneuro.2017.11.002","volume":"28","author":"MG Gottschalk","year":"2018","unstructured":"Gottschalk MG, Mortas P, Haman M, Ozcan S, Biemans B, Bahn S. Fluoxetine, not donepezil, reverses anhedonia, cognitive dysfunctions and hippocampal proteome changes during repeated social defeat exposure. Eur Neuropsychopharmacol. 2018;28:195\u2013210.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2249_CR207","doi-asserted-by":"crossref","unstructured":"Killgore WDS Effects of sleep deprivation on cognition. In: Kerkhof GA, Dongen HPA van BT-P in BR, editors. vol. 185, Elsevier; 2010. p. 105\u201329.","DOI":"10.1016\/B978-0-444-53702-7.00007-5"},{"key":"2249_CR208","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1017\/S1092852915000747","volume":"21","author":"RS McIntyre","year":"2016","unstructured":"McIntyre RS, Woldeyohannes HO, Soczynska JK, Maruschak NA, Wium-Andersen IK, Vinberg M, et al. Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project. CNS Spectr. 2016;21:362\u20136.","journal-title":"CNS Spectr"},{"key":"2249_CR209","doi-asserted-by":"crossref","unstructured":"Short MA, Chee MWL. Chapter 3 - Adolescent sleep restriction effects on cognition and mood. In: Van Dongen HPA, Whitney P, Hinson JM, Honn KA, Chee MWLBT-P in BR, editors. Sleep Deprivation Cogn., vol. 246, Elsevier; 2019. p. 55\u201371.","DOI":"10.1016\/bs.pbr.2019.02.008"},{"key":"2249_CR210","doi-asserted-by":"publisher","first-page":"14","DOI":"10.17756\/jnen.2019-047","volume":"5","author":"JJ Secades","year":"2019","unstructured":"Secades JJ. Citicoline in the treatment of cognitive impairment. J Neurol Exp Neurosci. 2019;5:14\u201326.","journal-title":"J Neurol Exp Neurosci"},{"key":"2249_CR211","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3109\/15622975.2011.639800","volume":"13","author":"SW Tang","year":"2012","unstructured":"Tang SW, Helmeste D, Leonard B. Is neurogenesis relevant in depression and in the mechanism of antidepressant drug action? A critical review. World J Biol Psychiatry. 2012;13:402\u201312.","journal-title":"World J Biol Psychiatry"},{"key":"2249_CR212","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.pscychresns.2011.12.006","volume":"203","author":"GS Alves","year":"2012","unstructured":"Alves GS, Karakaya T, Fu\u00dfer F, Kordulla M, O\u2019Dwyer L, Christl J, et al. Association of microstructural white matter abnormalities with cognitive dysfunction in geriatric patients with major depression. Psychiatry Res Neuroimaging. 2012;203:194\u2013200.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"2249_CR213","doi-asserted-by":"crossref","unstructured":"Meinert S, Nowack N, Grotegerd D, Repple J, Winter NR, Abheiden I, et al. Association of brain white matter microstructure with cognitive performance in major depressive disorder and healthy controls: a diffusion-tensor imaging study. Mol Psychiatry. 2021;27:1103\u201310.","DOI":"10.1038\/s41380-021-01330-8"},{"key":"2249_CR214","first-page":"199","volume":"33","author":"G Wagner","year":"2008","unstructured":"Wagner G, Koch K, Schachtzabel C, Reichenbach JR, Sauer H, Schl\u00f6sser RGM. Enhanced rostral anterior cingulate cortex activation during cognitive control is related to orbitofrontal volume reduction in unipolar depression. J Psychiatry Neurosci. 2008;33:199\u2013208.","journal-title":"J Psychiatry Neurosci"},{"key":"2249_CR215","doi-asserted-by":"crossref","unstructured":"Yamada S, Takahashi S, Ohoshi Y, Ishida T, Tsuji T, Shinosaki K, et al. Widespread white matter microstructural abnormalities and cognitive impairment in schizophrenia, bipolar disorder, and major depressive disorder: Tract-based spatial statistics study. Psychiatry Res Neuroimaging. 2020;298:111045.","DOI":"10.1016\/j.pscychresns.2020.111045"},{"key":"2249_CR216","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00873-8","volume":"10","author":"S Kakeda","year":"2020","unstructured":"Kakeda S, Watanabe K, Nguyen H, Katsuki A, Sugimoto K, Igata N, et al. An independent component analysis reveals brain structural networks related to TNF-\u03b1 in drug-na\u00efve, first-episode major depressive disorder: a source-based morphometric study. Transl Psychiatry. 2020;10:187.","journal-title":"Transl Psychiatry"},{"key":"2249_CR217","doi-asserted-by":"publisher","first-page":"449","DOI":"10.9758\/cpn.2021.19.3.449","volume":"19","author":"J Lim","year":"2021","unstructured":"Lim J, Sohn H, Kwon M-S, Kim B. White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder. Clin Psychopharmacol Neurosci. 2021;19:449\u201358.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"2249_CR218","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jad.2014.09.042","volume":"172","author":"S Choi","year":"2015","unstructured":"Choi S, Han K-M, Won E, Yoon B-J, Lee M-S, Ham B-J. Association of brain-derived neurotrophic factor DNA methylation and reduced white matter integrity in the anterior corona radiata in major depression. J Affect Disord. 2015;172:74\u201380.","journal-title":"J Affect Disord"},{"key":"2249_CR219","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/gps.4512","volume":"32","author":"SF Smagula","year":"2017","unstructured":"Smagula SF, Lotrich FE, Aizenstein HJ, Diniz BS, Krystek J, Wu GF, et al. Immunological biomarkers associated with brain structure and executive function in late\u2010life depression: exploratory pilot study. Int J Geriatr Psychiatry. 2017;32:692\u20139.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2249_CR220","doi-asserted-by":"publisher","first-page":"558","DOI":"10.2174\/1570159X13666150630171433","volume":"13","author":"B Bortolato","year":"2015","unstructured":"Bortolato B, Carvalho AF, Soczynska JK, Perini GI, McIntyre RS. The Involvement of TNF-\u03b1 in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. Curr Neuropharmacol. 2015;13:558\u201376.","journal-title":"Curr Neuropharmacol"},{"key":"2249_CR221","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1007\/s00213-014-3475-8","volume":"231","author":"T Mikoteit","year":"2014","unstructured":"Mikoteit T, Beck J, Eckert A, Hemmeter U, Brand S, Bischof R, et al. High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression. Psychopharmacol (Berl). 2014;231:2955\u201365.","journal-title":"Psychopharmacol (Berl)"},{"key":"2249_CR222","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00213-021-05790-2","volume":"238","author":"M Sagud","year":"2021","unstructured":"Sagud M, Nikolac Perkovic M, Dvojkovic A, Jaksic N, Vuksan-Cusa B, Zivkovic M, et al. Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram. Psychopharmacol (Berl). 2021;238:1575\u201384.","journal-title":"Psychopharmacol (Berl)"},{"key":"2249_CR223","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/15622975.2018.1425478","volume":"20","author":"S Wagner","year":"2019","unstructured":"Wagner S, Kayser S, Engelmann J, Schlicht KF, Dreim\u00fcller N, T\u00fcscher O, et al. Plasma brain-derived neurotrophic factor (pBDNF) and executive dysfunctions in patients with major depressive disorder. World J Biol Psychiatry. 2019;20:519\u201330.","journal-title":"World J Biol Psychiatry"},{"key":"2249_CR224","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s13346-017-0476-2","volume":"8","author":"M Le Nedelec","year":"2018","unstructured":"Le Nedelec M, Glue P, Winter H, Goulton C, Broughton L, Medlicott N. Acute low-dose ketamine produces a rapid and robust increase in plasma BDNF without altering brain BDNF concentrations. Drug Deliv Transl Res. 2018;8:780\u20136.","journal-title":"Drug Deliv Transl Res"},{"key":"2249_CR225","doi-asserted-by":"crossref","unstructured":"Perucca EBT-IR of N. Age\u2010Related Changes in Pharmacokinetics: Predictability and Assessment Methods. Neurobiol. Epilepsy Aging, vol. 81, Academic Press; 2007. p. 183\u201399.","DOI":"10.1016\/S0074-7742(06)81011-1"},{"key":"2249_CR226","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jad.2015.08.058","volume":"188","author":"JD Rosenblat","year":"2015","unstructured":"Rosenblat JD, Brietzke E, Mansur RB, Maruschak NA, Lee Y, McIntyre RS. Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications. J Affect Disord. 2015;188:149\u201359.","journal-title":"J Affect Disord"},{"key":"2249_CR227","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1007\/s40265-017-0819-9","volume":"77","author":"G Voegeli","year":"2017","unstructured":"Voegeli G, Cl\u00e9ry-Melin ML, Ramoz N, Gorwood P. Progress in elucidating biomarkers of antidepressant pharmacological treatment response: a systematic review and meta-analysis of the last 15 years. Drugs 2017;77:1967\u201386.","journal-title":"Drugs"},{"key":"2249_CR228","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00213-013-3186-6","volume":"230","author":"A Pringle","year":"2013","unstructured":"Pringle A, Browning M, Parsons E, Cowen PJ, Harmer CJ. Early markers of cognitive enhancement: developing an implicit measure of cognitive performance. Psychopharmacol (Berl). 2013;230:631\u20138.","journal-title":"Psychopharmacol (Berl)"},{"key":"2249_CR229","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.tics.2010.11.002","volume":"15","author":"M Husain","year":"2011","unstructured":"Husain M, Mehta MA. Cognitive enhancement by drugs in health and disease. Trends Cogn Sci. 2011;15:28\u201336.","journal-title":"Trends Cogn Sci"},{"key":"2249_CR230","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/00048670601109881","volume":"41","author":"RJ Porter","year":"2007","unstructured":"Porter RJ, Bourke C, Gallagher P. Neuropsychological impairment in major depression: its nature, origin and clinical significance. Aust N. Zeal J Psychiatry. 2007;41:115\u201328.","journal-title":"Aust N. Zeal J Psychiatry"},{"key":"2249_CR231","unstructured":"Zakzanis KK, Leach L, Kaplan E. On the nature and pattern of neurocognitive function in major depressive disorder. Neuropsychiatry, Neuropsychol Behav Neurol. 1998;11:111\u20139."},{"key":"2249_CR232","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1037\/a0028727","volume":"139","author":"HR Snyder","year":"2013","unstructured":"Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull. 2013;139:81.","journal-title":"Psychol Bull"},{"key":"2249_CR233","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1017\/S0033291701003634","volume":"31","author":"JR Crawford","year":"2001","unstructured":"Crawford JR, Deary IJ, Starr J, Whalley LJ. The NART as an index of prior intellectual functioning: a retrospective validity study covering a 66-year interval. Psychol Med. 2001;31:451\u20138.","journal-title":"Psychol Med"},{"key":"2249_CR234","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/bdi.12602","volume":"20","author":"KM Douglas","year":"2018","unstructured":"Douglas KM, Gallagher P, Robinson LJ, Carter JD, McIntosh VVW, Frampton CMA, et al. Prevalence of cognitive impairment in major depression and bipolar disorder. Bipolar Disord. 2018;20:260\u201374.","journal-title":"Bipolar Disord"},{"key":"2249_CR235","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3109\/08039488.2011.626870","volume":"66","author":"AM Svendsen","year":"2012","unstructured":"Svendsen AM, Kessing LV, Munkholm K, Vinberg M, Miskowiak KW. Is there an association between subjective and objective measures of cognitive function in patients with affective disorders? Nord J Psychiatry. 2012;66:248\u201353.","journal-title":"Nord J Psychiatry"},{"key":"2249_CR236","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-0815-8","volume":"16","author":"C Mohn","year":"2016","unstructured":"Mohn C, Rund BR. Neurocognitive profile in major depressive disorders: relationship to symptom level and subjective memory complaints. BMC Psychiatry. 2016;16:108.","journal-title":"BMC Psychiatry"},{"key":"2249_CR237","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1017\/S1041610219001923","volume":"32","author":"C Opdebeeck","year":"2020","unstructured":"Opdebeeck C. Self-reported memory and depression over time. Int Psychogeriatr. 2020;32:681\u20133.","journal-title":"Int Psychogeriatr"},{"key":"2249_CR238","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Disco. 2019;18:41\u201358.","journal-title":"Nat Rev Drug Disco"},{"key":"2249_CR239","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1017\/S1092852920000061","volume":"26","author":"CS Petersen","year":"2021","unstructured":"Petersen CS, Miskowiak KW. Toward a transdiagnostic neurocircuitry-based biomarker model for pro-cognitive effects: challenges, opportunities, and next steps. CNS Spectr. 2021;26:333\u20137.","journal-title":"CNS Spectr"},{"key":"2249_CR240","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3389\/fpsyg.2015.00328","volume":"6","author":"HR Snyder","year":"2015","unstructured":"Snyder HR, Miyake A, Hankin BL. Advancing understanding of executive function impairments and psychopathology: bridging the gap between clinical and cognitive approaches. Front Psychol. 2015;6:328.","journal-title":"Front Psychol"},{"key":"2249_CR241","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1080\/02699931.2011.613919","volume":"26","author":"U Zetsche","year":"2012","unstructured":"Zetsche U, D\u2019Avanzato C, Joormann J. Depression and rumination: Relation to components of inhibition. Cogn Emot. 2012;26:758\u201367.","journal-title":"Cogn Emot"},{"key":"2249_CR242","doi-asserted-by":"publisher","first-page":"103634","DOI":"10.1016\/j.brat.2020.103634","volume":"131","author":"ME Quinn","year":"2020","unstructured":"Quinn ME, Joormann J. Executive control under stress: Relation to reappraisal ability and depressive symptoms. Behav Res Ther. 2020;131:103634.","journal-title":"Behav Res Ther"},{"key":"2249_CR243","doi-asserted-by":"crossref","unstructured":"Greer TL, Sunderajan P, Grannemann BD, Kurian BT, Trivedi MH. Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction? Depress Res Treat. 2014;2014:627863.","DOI":"10.1155\/2014\/627863"},{"key":"2249_CR244","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1176\/ajp.2007.164.6.900","volume":"164","author":"J Raskin","year":"2007","unstructured":"Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164:900\u20139.","journal-title":"Am J Psychiatry"},{"key":"2249_CR245","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/npp.2015.52","volume":"40","author":"AR Mahableshwarkar","year":"2015","unstructured":"Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSE. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology 2015;40:2025\u201337.","journal-title":"Neuropsychopharmacology"},{"key":"2249_CR246","doi-asserted-by":"publisher","DOI":"10.1038\/srep28028","volume":"6","author":"Y Tian","year":"2016","unstructured":"Tian Y, Du J, Spagna A, Mackie M-A, Gu X, Dong Y, et al. Venlafaxine treatment reduces the deficit of executive control of attention in patients with major depressive disorder. Sci Rep. 2016;6:28028.","journal-title":"Sci Rep"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02249-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02249-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02249-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T15:07:43Z","timestamp":1668784063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02249-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":246,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2249"],"URL":"https:\/\/doi.org\/10.1038\/s41398-022-02249-6","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"assertion":[{"value":"8 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"484"}}